Ariad Pharmaceuticals Inc
ARIA
ARIA was delisted on the 15th of February, 2017.
179 hedge funds and large institutions have $888M invested in Ariad Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 22 closing their positions.
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
36% more capital invested
Capital invested by funds: $655M → $888M (+$233M)
6% more funds holding
Funds holding: 169 → 179 (+10)
2% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 50
8% less call options, than puts
Call options by funds: $32M | Put options by funds: $34.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$52M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$18.8M |
| 3 |
PC
PointState Capital
New York
|
+$10.3M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$9.38M |
| 5 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$8.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$12.8M |
| 2 |
Millennium Management
New York
|
-$8.89M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$8.88M |
| 4 |
JP Morgan Chase
New York
|
-$6.85M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.25M |
ARIA Hedge Fund Activity: Q4 2014 in Review
179 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2014, worth a combined $888M — up 36% from $655M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ARIA positions and 22 closed out — a net gain of 12 holders — while 49 added to existing stakes and 50 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $52M. The largest seller was HealthCor Management, exiting entirely with an estimated $12.8M sold.
- 179 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2014, up from 169 in Q3 2014.
- Funds reported $888M of Ariad Pharmaceuticals Inc stock for Q4 2014, up 36% quarter-over-quarter.
- 34 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2014 and 22 closed out, a net change of +12 holders.
- The largest Ariad Pharmaceuticals Inc buyer in Q4 2014 was Westfield Capital Management, an estimated $52M added.
- The largest Ariad Pharmaceuticals Inc seller in Q4 2014 was HealthCor Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q4 2014.